# Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma

> **NCT04054518** · PHASE2 · UNKNOWN · sponsor: **Tiago Biachi** · enrollment: 22 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04054518
- **Lead sponsor:** Tiago Biachi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054518, "Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04054518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*